Kardigan Inc. (KARD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for KARD, including 1 analyst rating, 1 press release or news item and 1 SEC filing. The most recent was published Nov 6, 2026.
KARD rankings
News · 26 weeks3+100%
2026-05-102026-11-01
Mix390d
- Analyst1(33%)
- Other1(33%)
- SEC Filings1(33%)
Activity · 52 weeks32 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
3 items- SECKardigan Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kardigan, Inc. (0002123613) (Filer)
- PRKardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic StenosisPrimary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; topline data expected 2H 2027 Novel real-world data help identify key markers of risk, rate of progression of disease and worsening outcomes in aortic stenosis, informing patient selection criteria and potential endpoints for Phase 3 registrational trial Company to host an investor webcast while at the American Heart Association Scientific Sessions on Saturday, November 7, 2026, at 8:00 AM ET Kardigan®, Inc. (NASDAQ:KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial
- ANALYSTH.C. Wainwright initiated coverage on Kardigan with a new price targetH.C. Wainwright initiated coverage of Kardigan with a rating of Buy and set a new price target of $42.00
KARD FAQ
8 questionsWhat does Kardigan Inc. do?
Kardigan is a clinical-stage precision cardiovascular company developing medicines that target the root cause of diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies.What is the latest news on KARD?
In the last 30 days Quantisnow tracked 3 wire items for KARD: 1 analyst rating, 1 press release or news item and 1 SEC filing. The most recent was published on November 6, 2026.Where does KARD stock trade?
Kardigan Inc. (KARD) is listed on NASDAQ.What sector and industry is KARD in?
Kardigan Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kardigan Inc. go public?
Kardigan Inc. (KARD) completed its IPO in 2026.What are analysts saying about KARD?
Kardigan Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $42.00 price target on 2026-11-04. Recent price targets cluster around $42.00.What companies are similar to KARD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KARD side-by-side with any of them on Quantisnow.How can I track KARD on Quantisnow?
Quantisnow aggregates Kardigan Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KARD to receive live email and push alerts on every new disclosure.